Open AccessActivity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species
Author(s) -
J. Paul O'Keefe,
Frank R. Venezio,
Cathy A. DiVincenzo,
Kari L. Shatzer
Publication year - 1987
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.31.12.2002
Subject(s) - bacteroides fragilis , cefoxitin , ceftizoxime , cefotetan , imipenem , microbiology and biotechnology , ticarcillin , cefotaxime , latamoxef , clavulanic acid , moxalactam , antibiotics , biology , mezlocillin , piperacillin , bacteria , amoxicillin , pseudomonas aeruginosa , antibiotic resistance , genetics , staphylococcus aureus
The in vitro activities of beta-lactam antibiotics against Bacteroides fragilis and B. fragilis group isolates are presented. Clinical isolates from 1986 were compared with strains from 1979 to 1982. Imipenem, ticarcillin-clavulanic acid, and ceftizoxime were the most active agents. Cefotetan was equivalent to cefoxitin against B. fragilis but less active against B. fragilis group isolates. Enhancement of cefotaxime by its desacetyl metabolite was minimal.